Consolidated Statements of Stockholders' Equity - USD ($)
|
Common stock
Retroactive Application Of Recapitalization
|
Common stock
Adjusted Balance
|
Common stock |
Additional Paid-in Capital
Retroactive Application Of Recapitalization
|
Additional Paid-in Capital
Adjusted Balance
|
Additional Paid-in Capital |
Accumulated Deficit
Retroactive Application Of Recapitalization
|
Accumulated Deficit
Adjusted Balance
|
Accumulated Deficit |
Retroactive Application Of Recapitalization |
Adjusted Balance |
Total |
| Balance at the beginning at Dec. 31, 2019 |
|
|
|
|
|
|
|
|
|
|
$ (29,096,000)
|
|
$ 29,096,000
|
| Balance at the beginning at Dec. 31, 2019 |
|
$ 6,000
|
$ 7,000
|
$ 1,000
|
$ 26,145,000
|
$ 26,145,000
|
|
$ 2,945,000
|
$ (13,252,000)
|
$ (16,197,000)
|
$ 29,096,000
|
$ 12,900,000
|
(16,196,000)
|
| Balance at the beginning (in shares) at Dec. 31, 2019 |
|
61,573,943
|
68,787,673
|
7,213,730
|
|
|
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net Income (Loss) |
|
|
|
|
|
|
|
|
|
(14,375,000)
|
|
|
(14,375,000)
|
| Expenses related to issuance of warrants |
|
|
|
|
|
|
$ 16,000
|
|
|
|
|
|
16,000
|
| Beneficial Conversion feature on convertible debt |
|
|
|
|
|
|
5,125,000
|
|
|
|
|
|
5,125,000
|
| Stock options exercised (in shares) |
|
|
|
1,097,370
|
|
|
|
|
|
|
|
|
|
| Stock options exercised |
|
|
|
$ 1,097,370
|
|
|
24,000
|
|
|
|
|
|
24,000
|
| Stock-based compensation expense |
|
|
|
|
|
|
182,000
|
|
|
|
|
|
182,000
|
| Balance at the end at Dec. 31, 2020 |
|
|
|
$ 7,000
|
|
|
31,492,000
|
|
|
(27,627,000)
|
|
|
3,872,000
|
| Balance at the end (in shares) at Dec. 31, 2020 |
|
|
|
69,885,043
|
|
|
|
|
|
|
|
|
|
| Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Net Income (Loss) |
|
|
|
|
|
|
|
|
|
18,092,000
|
|
|
18,092,000
|
| Business Combination, net of redemptions and transaction costs of $47,888 |
|
|
|
$ 6,000
|
|
|
394,587,000
|
|
|
|
|
|
394,593,000
|
| Business Combination, net of redemptions and transaction costs of $47,888 (in shares) |
|
|
|
63,039,829
|
|
|
|
|
|
|
|
|
|
| Beneficial Conversion feature on convertible debt |
|
|
|
|
|
|
4,875,000
|
|
|
|
|
|
4,875,000
|
| Redemption of Series A-1 redeemable preferred stock |
[1] |
|
|
|
|
|
(6,041,000)
|
|
|
|
|
|
(6,041,000)
|
| Redemption of Series A-1 redeemable preferred stock (in shares) |
[1] |
|
|
(1,065,432)
|
|
|
|
|
|
|
|
|
|
| Issuance of Series B redeemable preferred stock net of issuance costs of $4,511 and settlement of associated convertible preferred stock liability |
[1] |
|
|
$ 3,000
|
|
|
140,436,000
|
|
|
|
|
|
140,439,000
|
| Issuance of Series B redeemable preferred stock net of issuance costs of $4,511 and settlement of associated convertible preferred stock liability (in shares) |
[1] |
|
|
27,930,997
|
|
|
|
|
|
|
|
|
|
| Warrants exercised |
|
|
|
$ 1,000
|
|
|
14,000
|
|
|
|
|
|
15,000
|
| Stock options exercised (in shares) |
|
|
|
1,160,930
|
|
|
|
|
|
|
|
|
|
| Warrants exercised (in shares) |
|
|
|
6,606,621
|
|
|
|
|
|
|
|
|
|
| Issuance Costs |
|
|
|
|
|
|
|
|
|
|
|
|
4,511,000
|
| Stock options exercised |
|
|
|
$ 1,160,930
|
|
|
106,000
|
|
|
|
|
|
106,000
|
| Stock-based compensation expense |
|
|
|
|
|
|
2,714,000
|
|
|
|
|
|
2,714,000
|
| Balance at the end at Dec. 31, 2021 |
|
|
|
$ 17,000
|
|
|
$ 568,183,000
|
|
|
$ (9,535,000)
|
|
|
$ 558,665,000
|
| Balance at the end (in shares) at Dec. 31, 2021 |
|
|
|
167,557,988
|
|
|
|
|
|
|
|
|
|
|
|